Skip to main content
SpringerLink
Log in

Synthetic Cannabinoid Use

  • Chapter
  • First Online:
Cannabis Use Disorders

Abstract

The emergence of smokable herbal products containing synthetic cannabinoids (SCs) is becoming increasingly popular in the new psychoactive substance use landscape. These compounds are mainly sold online (darknet) as an alternative to controlled and regulated psychoactive substances such as cocaine, MDMA and opiates. In the early 2000s, SCs became popular under brand names such as Spice in Europe and K2 in the USA. Substantial variations may exist in content and concentration of SC compounds in many available products, even within the same brand or batch. Clinical effects of SCs, as with other new psychoactive substances (NPSs), depend on the individual, the dose and the route of administration. The majority of their psychoactive effects are comparable to those of cannabis. Distinct pharmacological properties and the metabolism of SCs relative to Δ9-THC may contribute to the observed toxicity. Early evidence suggests that adverse somatic and psychiatric outcomes associated with the use of SCs may be more prevalent and more severe than those arising from cannabis use. The aim of the current chapter is to review the available data regarding the effects and consequences of SC use in humans. A literature search was performed on two representative databases, PubMed and Science Direct, and various websites as mentioned above. The terms used for the database search were “synthetic cannabinoids”, “spice”, “K2”, “synthetic cannabis”, “legal highs”, “new psychoactive substances”, “harmful use”, “adverse effects” and “fatalities”. The search was limited to the years 2005 to 2017. The literature search conducted led to the identification of potentially 122 relevant articles. All articles were screened from their abstracts to determine their relevance in the framework of the current review.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Grotenhermen F. Cannabinoids. Curr Drug Targets CNS Neurol Disord. 2005;4:507–30.

    Article  CAS  PubMed  Google Scholar 

  2. Pertwee RG, et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB(1) and CB(2). Pharmacol Rev. 2010;62:588–631.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Fantegrossi WE, et al. Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Delta(9)-THC: mechanism underlying greater toxicity? Life Sci. 2014;97:45–54.

    Article  CAS  PubMed  Google Scholar 

  4. Howlett AC, et al. Endocannabinoid tone versus constitutive activity of cannabinoid receptors. Br J Pharmacol. 2011;163:1329–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Thakur GA, et al. Methods for the synthesis of cannabinergic ligands. Methods Mol Med. 2006;123:113–48.

    CAS  PubMed  Google Scholar 

  6. Johnson LA, et al. Current "legal highs". J Emerg Med. 2013;44:1108–15.

    Article  PubMed  Google Scholar 

  7. Mounteney J, et al. The drug situation in Europe: an overview of data available on illicit drugs and new psychoactive substances from European monitoring in 2015. Addiction. 2016;111:34–48.

    Article  PubMed  Google Scholar 

  8. Seely KA, et al. Forensic investigation of K2, spice, and "bath salt" commercial preparations: a three-year study of new designer drug products containing synthetic cannabinoid, stimulant, and hallucinogenic compounds. Forensic Sci Int. 2013;233:416–22.

    Article  CAS  PubMed  Google Scholar 

  9. Castellanos D, Gralnik LM. Synthetic cannabinoids 2015: an update for pediatricians in clinical practice. World J Clin Pediatr. 2016;5:16–24.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Karila L. Emergency of synthetic drugs in the general landscape of addiction. Rev Prat. 2012;62:661–3.

    PubMed  Google Scholar 

  11. EMCDDA. 2015. PERSPECTIVES ON DRUGS – Synthetic cannabinoids in Europe – emcdda.europa.eu/topics/pods/synthetic-cannabinoids. Last accessed 2 Apr 2016.

  12. Simolka K, et al. Analysis of synthetic cannabinoids in “spice-like” herbal highs: snapshot of the German market in summer 2011. Anal Bioanal Chem. 2012;404:157–71.

    Article  CAS  PubMed  Google Scholar 

  13. Gunderson EW, et al. “Spice” and “K2” herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans. Am J Addict. 2012;21:320–6.

    Article  PubMed  Google Scholar 

  14. EMCDDA. Understanding the ‘spice’ phenomenon, EMCDDA thematic paper, publications Office of the European. Luxembourg: Union; 2009.

    Google Scholar 

  15. Fattore L, Fratta W. Beyond THC: the new generation of cannabinoid designer drugs. Front Behav Neurosci. 2011;5:60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Wiley JL, et al. Hijacking of basic research: the case of synthetic cannabinoids. Methods Rep 2011, 2011, 17971..

    Google Scholar 

  17. Ernst L, et al. Synthetic cannabinoids in “spice-like” herbal blends: first appearance of JWH-307 and recurrence of JWH-018 on the German market. Forensic Sci Int. 2012;222:216–22.

    Article  CAS  PubMed  Google Scholar 

  18. Dresen S, et al. Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds. J Mass Spectrom. 2010;45:1186–94.

    Article  CAS  PubMed  Google Scholar 

  19. Atwood BK, et al. CP47,497-C8 and JWH073, commonly found in 'Spice' herbal blends, are potent and efficacious CB(1) cannabinoid receptor agonists. Eur J Pharmacol. 2011;659:139–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Karila L, et al. The synthetic cannabinoids phenomenon. Curr Pharm Des. 2016;22:6420–5.

    Article  CAS  PubMed  Google Scholar 

  21. Cottencin O, et al. New designer drugs (synthetic cannabinoids and synthetic cathinones): review of literature. Curr Pharm Des. 2014;20:4106–11.

    Article  CAS  PubMed  Google Scholar 

  22. UNDOC. 2011. Synthetic cannabinoids in herbal products in: https://www.unodc.org/documents/scientific/Synthetic_Cannabinoids.pdf. Last accessed 1 Apr 2016.

  23. EMCDDA. 2014. European Monitoring Centre for Drugs and Drug Addiction European Drug Report 2014: Trends and developments Luxembourg: Publications Office of the European Union 2014—80 pp.

    Google Scholar 

  24. Nelson ME, et al. Emerging drugs of abuse. Emerg Med Clin North Am. 2014;32:1–28.

    Article  PubMed  Google Scholar 

  25. Archer JR, et al. Trend analysis of anonymised pooled urine from portable street urinals in Central London identifies variation in the use of novel psychoactive substances. Clin Toxicol. 2014;52:160–5.

    Article  CAS  Google Scholar 

  26. Castaneto MS, et al. Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend. 2014;144:12–41.

    Article  CAS  PubMed  Google Scholar 

  27. Survey, M.t.F. 2014. Overview of findings (2014) http://www.drugabuse.gov/related-topics/trends-statistics/monitoring-future/monitoring-future-survey-overview-findings-2014. Last accessed 1 Apr 2016.

  28. Palamar JJ, et al. Synthetic cannabinoid use among high school seniors. Pediatrics. 2017;140(4):pii: e20171330.

    Article  Google Scholar 

  29. NIDA Monitoring the future study: trends in prevalence of various drugs. www.drugabuse.gov/trends-statistics/monitoring-future-study-trends-in-prevalence-various-drugs. Accessed Oct 2017.

  30. Smith K, Flatley J. Drug misuse declared: findings from the 2010/11 British crime survey. Home Office, London: England and Wales; 2011.

    Google Scholar 

  31. Statistics, O.f.N. Drug misuse declared: findings from the 2011/12 crime survey for England and Wales. London: Home Office; 2012.

    Google Scholar 

  32. Survey GD. 2012. Global drug survey. http://www.globaldrugsurvey.com/wp-content/uploads/DRUG_SURVEY_FINAL_1.pdf. Last accessed 1 Apr 2016.

  33. Werse B, et al. MoSyD, Jahresbericht 2013, Drogentrends in Frankfurt am Main, Centre for Drug Research, 2014.

    Google Scholar 

  34. INPES. 2014. Usages de psychoactifs illicites en France: les résultats du Baromètre santé Inpes 2014 in: http://www.inpes.sante.fr/30000/actus2015/023-drogues-illicites.asp. Last accessed 1 Apr 2016.

  35. Spilka S, et al. Drug use among 17-year-olds: results of the ESCAPAD 2014 survey. Tendances. 2015;100:1–8.

    Google Scholar 

  36. SOOD. Spanish observatory on drugs. Survey on Alcohol and Drugs in Spain (EDADES), 2013.

    Google Scholar 

  37. Gunderson EW, et al. A survey of synthetic cannabinoid consumption by current cannabis users. Subst Abus. 2014;35:184–9.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Tai S, Fantegrossi WE. Synthetic cannabinoids: pharmacology, behavioral effects, and abuse potential. Curr Addict Rep. 2014;1:129–36.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Prosser JM, Nelson LS. The toxicology of bath salts: a review of synthetic cathinones. J Med Toxicol. 2012;8:33–42.

    Article  PubMed  Google Scholar 

  40. Gurney SM, et al. Pharmacology, toxicology, and adverse effects of synthetic cannabinoid drugs. Forensic Sci Rev. 2014;26:53–78.

    CAS  PubMed  Google Scholar 

  41. Auwarter V, et al. Spice’ and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrum. 2009;44:832–7.

    Article  CAS  Google Scholar 

  42. Scocard A, et al. Synthetic cannabinoids: a new addiction matrix. Presse Med. 2017;46:11–22.

    Article  PubMed  Google Scholar 

  43. Tait RJ, et al. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin Toxicol (Phila). 2016;54:1–13.

    Article  CAS  Google Scholar 

  44. Weaver MF, et al. Designer drugs 2015: assessment and management. Addict Sci Clin Pract. 2015;10:8.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Heath TS, et al. Acute intoxication caused by a synthetic cannabinoid in two adolescents. J Pediatr Pharmacol Ther. 2012;17:177–81.

    PubMed  PubMed Central  Google Scholar 

  46. Hermanns-Clausen M, et al. Acute intoxication by synthetic cannabinoids--four case reports. Drug Test Anal. 2013;5:790–4.

    Article  CAS  PubMed  Google Scholar 

  47. Atik SU, et al. Cardiovascular side effects related with use of synthetic cannabinoids "bonzai" : two case reports. Turk Pediatri Arsivi. 2015;50:61–4.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Kane EM, et al. Bradycardia and hypotension after synthetic cannabinoid use: a case series. Am J Emerg Med. 2016;34(10):2055.e1.

    Article  Google Scholar 

  49. Lapoint J, et al. Severe toxicity following synthetic cannabinoid ingestion. Clin Toxicol (Phila). 2011;49:760–4.

    Article  CAS  Google Scholar 

  50. Von Der Haar J, et al. Synthetic cannabinoids and their effects on the cardiovascular system. J Emerg Med. 2016;50:258–62.

    Google Scholar 

  51. Wells DL, Ott CA. The "new" marijuana. Ann Pharmacother. 2011;45:414–7.

    Article  CAS  PubMed  Google Scholar 

  52. Pacher P, et al. Cardiovascular pharmacology of cannabinoids. Handb Exp Pharmacol. 2005:599–625.

    Google Scholar 

  53. McIlroy G, et al. Acute myocardial infarction, associated with the use of a synthetic adamantyl-cannabinoid: a case report. BMC Pharmacol Toxicol. 2016;17:2.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  54. Raheemullah A, Laurence TN. Repeated thrombosis after synthetic cannabinoid use. J Emerg Med. 2016;51:540–3.

    Article  PubMed  Google Scholar 

  55. Cha HJ, et al. Neurotoxicity of synthetic cannabinoids JWH-081 and JWH-210. Biomol Ther. 2015;23:597–603.

    Article  CAS  Google Scholar 

  56. Mills B, et al. Synthetic cannabinoids. Am J Med Sci. 2015;350:59–62.

    Article  PubMed  Google Scholar 

  57. Kak M, et al. Buzz juice: neurological sequelae of synthetic cannabinoids. J Clin Neurosci. 2017;37:43.

    Article  PubMed  Google Scholar 

  58. Rose DZ, et al. Hemorrhagic stroke following use of the synthetic marijuana "spice". Neurology. 2015;85:1177–9.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Moeller S, et al. Ischemic stroke associated with the use of a synthetic cannabinoid (spice). Asian J Psychiatr. 2017;25:127–30.

    Article  PubMed  Google Scholar 

  60. Takematsu M, et al. A case of acute cerebral ischemia following inhalation of a synthetic cannabinoid. Clin Toxicol (Phila). 2014;52:973–5.

    Article  CAS  Google Scholar 

  61. Bernson-Leung ME, et al. Synthetic cannabis and acute ischemic stroke. J Stroke Cerebrovasc Dis. 2014;23:1239–41.

    Article  PubMed  Google Scholar 

  62. Freeman MJ, et al. Ischemic stroke after use of the synthetic marijuana "spice". Neurology. 2013;81:2090–3.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Fellner A, et al. Synthetic cannabinoids revealing adrenoleukodystrophy. J Clin Neurosci. 2016;24:155–6.

    Article  PubMed  Google Scholar 

  64. Karila L, et al. Acute and long-term effects of cannabis use: a review. Curr Pharm Des. 2014;20:4112–8.

    Article  CAS  PubMed  Google Scholar 

  65. Hopkins CY, Gilchrist BL. A case of cannabinoid hyperemesis syndrome caused by synthetic cannabinoids. J Emerg Med. 2013;45:544–6.

    Article  PubMed  Google Scholar 

  66. Argamany JR, et al. Synthetic cannabinoid hyperemesis resulting in rhabdomyolysis and acute renal failure. Am J Emerg Med. 2016;34(765):e761–2.

    Google Scholar 

  67. Sevinc MM, et al. Extraordinary cause of acute gastric dilatation and hepatic portal venous gas: chronic use of synthetic cannabinoid. World J Gastroenterol. 2015;21:10704–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Solimini R, et al. Hepatotoxicity associated to synthetic cannabinoids use. Eur Rev Med Pharmacol Sci. 2017;21:1–6.

    CAS  PubMed  Google Scholar 

  69. Alp A, et al. (2017) synthetic cannabinoids in the kidneys. Rev Assoc Med Bras. 1992;63:10–2.

    Article  Google Scholar 

  70. Pendergraft WF 3rd, et al. Nephrotoxic effects of common and emerging drugs of abuse. Clin J Am Soc Nephrol. 2014;9:1996–2005.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Park M, et al. Determination of XLR-11 and its metabolites in hair by liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2015;114:184–9.

    Article  CAS  PubMed  Google Scholar 

  72. Centers for Disease, C. and Prevention. Acute kidney injury associated with synthetic cannabinoid use--multiple states, 2012. MMWR Morb Mortal Wkly Rep. 2013;62:93–8.

    Google Scholar 

  73. Thornton SL, et al. Synthetic cannabinoid use associated with acute kidney injury. Clin Toxicol (Phila). 2013;51:189–90.

    Article  Google Scholar 

  74. Kamel M, Thajudeen B. A case of acute kidney injury and calcium oxalate deposition associated with synthetic cannabinoids. Saudi J Kidney Dis Transpl. 2015;26:802–3.

    Article  PubMed  Google Scholar 

  75. Zhao A, et al. Rhabdomyolysis and acute kidney injury requiring Dialysis as a result of concomitant use of atypical neuroleptics and synthetic cannabinoids. Case reports in nephrology 2015, 235982.

    Google Scholar 

  76. Durand D, et al. Psychosis and severe rhabdomyolysis associated with synthetic cannabinoid use: a case report. Clin Schizophr Relat Psychoses. 2015;8:205–8.

    Article  PubMed  Google Scholar 

  77. Sweeney B, et al. Hyperthermia and severe rhabdomyolysis from synthetic cannabinoids. Am J Emerg Med. 2016;34(121):e121–2.

    Google Scholar 

  78. Drenzek C, et al. Notes from the field: severe illness associated with synthetic cannabinoid use — Brunswick, Georgia, 2013; Morbidity and Mortality Weekly Reports; November 22, 2013; http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6246a7.htm. Accessed 18 Oct 2017.

  79. White CM. The pharmacologic and clinical effects of illicit synthetic cannabinoids. J Clin Pharmacol. 2017;57:297–304.

    Article  CAS  PubMed  Google Scholar 

  80. Alhadi S, et al. High times, low sats: diffuse pulmonary infiltrates associated with chronic synthetic cannabinoid use. J Med Toxicol. 2013;9:199–206.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Loschner A, et al.. Diffuse alveolar hemorrhage: add “greenhouse effect” to the growing list; chest 140:149A; 2011; http://journal.publications.chestnet.org/article.aspx?articleid=1088295. Last accessed 1 Apr, 2016.

  82. Drenzek C, et al. Notes from the field: severe illness associated with synthetic cannabinoid use—Brunswick, Georgia, 2013; Morbidity and Mortality Weekly Reports; November 22, 2013; http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6246a7.htm. Last accessed 1 Apr 2016.

  83. Biswas A, et al. Synthetic cannabinoids as a cause for black carbonaceous bronchoalveolar lavage. BMJ Case Rep. 2015;2015

    Google Scholar 

  84. Inci R, et al. Dermatological aspects of synthetic cannabinoid addiction. Cutan Ocul Toxicol. 2017;36:125–31.

    Article  CAS  PubMed  Google Scholar 

  85. Ustundag MF, et al. Synthetic cannabis-induced mania. Case Rep Psychiatry. 2015, 310930.

    Google Scholar 

  86. Muller HH, et al. The behavioral profile of spice and synthetic cannabinoids in humans. Brain Res Bull. 2015;126:3.

    Article  PubMed  CAS  Google Scholar 

  87. Peglow S, et al. Synthetic cannabinoid induced psychosis in a previously nonpsychotic patient. Am J Addict. 2012;21:287–8.

    Article  PubMed  Google Scholar 

  88. Meijer KA, et al. Smoking synthetic marijuana leads to self-mutilation requiring bilateral amputations. Orthopedics. 2014;37:e391–4.

    Article  PubMed  Google Scholar 

  89. Klavz J, et al. Suicide attempt with a mix of synthetic cannabinoids and synthetic cathinones: case report of non-fatal intoxication with AB-CHMINACA, AB-FUBINACA, alpha-PHP, alpha-PVP and 4-CMC. Forensic Sci Int. 2016;265:121–4.

    Article  CAS  PubMed  Google Scholar 

  90. Khan M, et al. Catatonia secondary to synthetic cannabinoid use in two patients with no previous psychosis. Am J Addict. 2016;25:25–7.

    Article  PubMed  Google Scholar 

  91. van Amsterdam J, et al. The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects. J Psychopharmacol. 2015;29:254–63.

    Article  CAS  PubMed  Google Scholar 

  92. Tyndall JA, et al. An outbreak of acute delirium from exposure to the synthetic cannabinoid AB-CHMINACA. Clin Toxicol (Phila). 2015;53:950–6.

    Article  CAS  Google Scholar 

  93. Morkl S, et al. Acute psychosis after consumption of synthetic cannabinoids. Fortschr Neurol Psychiatr. 2016;84:150–4.

    Article  CAS  PubMed  Google Scholar 

  94. Fattore L. Synthetic cannabinoids-further evidence supporting the relationship between cannabinoids and psychosis. Biol Psychiatry. 2016;79:539–48.

    Article  CAS  PubMed  Google Scholar 

  95. Spaderna M, et al. Spicing things up: synthetic cannabinoids. Psychopharmacology. 2013;228:525–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Chavant F, et al. New synthetic drugs in addictovigilance. Therapie. 2015;70:167–89.

    Article  PubMed  Google Scholar 

  97. Sampson CS, et al. Withdrawal seizures seen in the setting of synthetic cannabinoid abuse. Am J Emerg Med. 2015;33(1712):e1713.

    Google Scholar 

  98. Macfarlane V, Christie G. Synthetic cannabinoid withdrawal: a new demand on detoxification services. Drug Alcohol Rev. 2015;34:147–53.

    Article  PubMed  Google Scholar 

  99. Andrabi S, et al. New drugs of abuse and withdrawal syndromes. Emerg Med Clin North Am. 2015;33:779–95.

    Article  PubMed  Google Scholar 

  100. Zimmermann US, et al. Withdrawal phenomena and dependence syndrome after the consumption of "spice gold". Dtsch Arztebl Int. 2009;106:464–7.

    PubMed  PubMed Central  Google Scholar 

  101. Nacca N, et al. The synthetic cannabinoid withdrawal syndrome. J Addict Med. 2013;7:296–8.

    Article  CAS  PubMed  Google Scholar 

  102. Law R, et al. Notes from the field: increase in reported adverse health effects related to synthetic cannabinoid use - United States, January-may 2015. MMWR Morb Mortal Wkly Rep. 2015;64:618–9.

    PubMed  PubMed Central  Google Scholar 

  103. Monte AA, et al. An outbreak of exposure to a novel synthetic cannabinoid. N Engl J Med. 2014;370:389–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  104. Schwartz MD, et al. A common source outbreak of severe delirium associated with exposure to the novel synthetic cannabinoid ADB-PINACA. J Emerg Med. 2015;48:573–80.

    Article  PubMed  PubMed Central  Google Scholar 

  105. Kasper AM, et al. Severe illness associated with reported use of synthetic cannabinoids – Mississippi, April 2015. MMWR Morb Mortal Wkly Rep. 2015;64:1121–2.

    Article  PubMed  Google Scholar 

  106. Springer YP, et al. Increase in adverse reactions associated with use of synthetic cannabinoids – anchorage, Alaska, 2015–2016. MMWR Morb Mortal Wkly Rep. 2016;65:1108–11.

    Article  PubMed  Google Scholar 

  107. Katz KD, et al. Case series of synthetic cannabinoid intoxication from one toxicology center. West J Emerg Med. 2016;17:290–4.

    Article  PubMed  PubMed Central  Google Scholar 

  108. Adams AJ, et al. “Zombie” outbreak caused by the synthetic cannabinoid AMB-FUBINACA in New York. N Engl J Med. 2017;376:235–42.

    Article  CAS  PubMed  Google Scholar 

  109. Labay LM, et al. Synthetic cannabinoid drug use as a cause or contributory cause of death. Forensic Sci Int. 2016;260:31–9.

    Article  CAS  PubMed  Google Scholar 

  110. Behonick G, et al. Four postmortem case reports with quantitative detection of the synthetic cannabinoid, 5F-PB-22. J Anal Toxicol. 2014;38:559–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  111. Hasegawa K, et al. Postmortem distribution of MAB-CHMINACA in body fluids and solid tissues of a human cadaver. Forensic Toxicol. 2015;33:380–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  112. Westin AA, et al. Sudden cardiac death following use of the synthetic cannabinoid MDMB-CHMICA. J Anal Toxicol. 2016;40:86–7.

    CAS  PubMed  Google Scholar 

  113. Ibrahim S, et al. A unique case of cardiac arrest following K2 abuse. Case Rep Cardiol. 2014;2014:120607.

    PubMed  PubMed Central  Google Scholar 

  114. Davis C, Boddington D. Teenage cardiac arrest following abuse of synthetic cannabis. Heart Lung Circ. 2015;24:e162–3.

    Article  CAS  PubMed  Google Scholar 

  115. Adamowicz P. Fatal intoxication with synthetic cannabinoid MDMB-CHMICA. Forensic Sci Int. 2016;261:e5–e10.

    Article  CAS  PubMed  Google Scholar 

  116. Shanks KG, et al. Case reports of synthetic cannabinoid XLR-11 associated fatalities. Forensic Sci Int. 2015;252:e6–9.

    Article  CAS  PubMed  Google Scholar 

  117. Shanks KG, et al. Death associated with the use of the synthetic cannabinoid ADB-FUBINACA. J Anal Toxicol. 2016;40:236–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  118. Shanks KG, Behonick GS. Death after use of the synthetic cannabinoid 5F-AMB. Forensic Sci Int. 2016;262:e21–4.

    Article  CAS  PubMed  Google Scholar 

  119. Debruyne D, Le Boisselier R. Emerging drugs of abuse: current perspectives on synthetic cannabinoids. Subst Abuse Rehabil. 2015;6:113–29.

    Article  PubMed  PubMed Central  Google Scholar 

  120. Sarpong I, Jones F. A critical analysis of national policy relating to legal highs. Nurs Stand. 2014;28:35–41.

    Article  PubMed  Google Scholar 

  121. Drug Enforcement Administration, D.o.J. Schedules of controlled substances: extension of temporary placement of PB-22, 5F-PB-22, AB-FUBINACA and ADB-PINACA in schedule I of the controlled substances act. Final order. Fed Regist. 2016;81:6175–7.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Psychiatre – Addictologue, Hopital Universitaire Paul Brousse, Villejuif, France

    Laurent Karila & Amine Benyamina

  2. Université Paris Sud – INSERM U1000, Paris, France

    Laurent Karila

  3. Centre de Recherche en Epidémiologie et Santé des Populations (CESP), INSERM, Paris, France

    Amine Benyamina

Authors
  1. Laurent Karila
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amine Benyamina
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Laurent Karila .

Editor information

Editors and Affiliations

  1. Division of Pharma & Med Cons Drug Abuse, NIDA, NIH, Department of Health & Human Services, Bethesda, MD, USA

    Ivan D. Montoya

  2. Division of Extramural Research, National Institute on Drug Abuse Division of Extramural Research, Bethesda, MD, USA

    Susan R. B. Weiss

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Karila, L., Benyamina, A. (2019). Synthetic Cannabinoid Use. In: Montoya, I., Weiss, S. (eds) Cannabis Use Disorders. Springer, Cham. https://doi.org/10.1007/978-3-319-90365-1_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-90365-1_16

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-90364-4

  • Online ISBN: 978-3-319-90365-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation